Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection

NCT00782353 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: ANA598 200 mg bid or placebo
DRUG: ANA598 400 mg bid or placebo
DRUG: ANA598 800 mg bid or placebo

Sponsor

Hoffmann-La Roche